---
title: "Neurocrine Biosciences: weighing benefit and risk for a rare-disease drug"
id: "stat-news-2-stat-neurocrine-biosciences-and-the-delicate-balance-of-benefit-and-risk"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-2-stat-neurocrine-biosciences-and-the-delicate-balance-of-benefit-and-risk"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/08/13/neurocrine-biosciences-vykat-prader-willi-2/?utm_campaign=rss"
published_at: "2026-08-13T10:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Neurocrine Biosciences: weighing benefit and risk for a rare-disease drug
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-2-stat-neurocrine-biosciences-and-the-delicate-balance-of-benefit-and-risk
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/08/13/neurocrine-biosciences-vykat-prader-willi-2/?utm_campaign=rss)
- **Published At:** 2026-08-13T10:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Neurocrine Biosciences is at the center of a debate about the balance between therapeutic benefit and safety for a drug developed for a **rare disease**. The full reporting is behind a STAT+ paywall; only a portion of the article is publicly available. - The public excerpt outlines a common regulatory and clinical dilemma: small trials in rare diseases can show modest efficacy and manageable adverse events, supporting approval when disease burden is severe. - After approval and broader clinical use, clinicians reported a small number of **deaths** and an apparent rise in serious adverse events requiring hospitalization — events not observed in the pre-approval trial. - The article frames this as a pattern where a drug’s **real-world safety profile** can look substantially worse than what a small, controlled clinical trial indicated. - The piece is presented as an exclusive STAT+ story and the detailed evidence, numbers, and sources from the remainder of the report are not available in the public excerpt. - Because the subscriber-only portion is not available, specific data points, the drug’s name, the size and design of the trial, the timing and circumstances of the reported postmarketing events, and regulatory actions (if any) were not reported in the accessible source. - The available text emphasizes ethical and practical tensions faced by patients, caregivers, clinicians, and regulators when balancing modest benefits against potentially severe, even fatal, harms once a therapy is used widely. - The excerpt highlights a recurring challenge in rare-disease therapeutics: approvals based on limited evidence can lead to difficult decisions when new safety signals emerge in clinical practice. - The article’s tone is investigative and cautionary, noting the need for continued vigilance and transparent reporting of post-approval safety data. - Readers should be aware that the full reporting with supporting details is restricted to STAT+ subscribers and was not included in the provided source material.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/08/13/neurocrine-biosciences-vykat-prader-willi-2/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/13/neurocrine-biosciences-vykat-prader-willi-2/?utm_campaign=rss) [chronic disease](https://www.statnews.com/topic/chronic-disease/) [aging](https://www.statnews.com/topic/aging/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)Opinion[Adam’s Biotech Scorecard](https://www.statnews.com/category/adams-biotech-scorecard/) # Neurocrine Biosciences and the delicate balance of benefit and risk ## A rare disease drug is once again forcing difficult decisions for patients and their caregivers * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/13/neurocrine-biosciences-vykat-prader-willi-2/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_5440559-645x645.jpg) Adobe ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Aug. 13, 2026 Senior Writer, Biotech ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. _This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up[here](https://www.statnews.com/signup/scorecard/) to get it delivered to their inbox._ A drug for a rare disease is evaluated in a small clinical trial. The treatment is modestly effective with manageable side effects. Balanced against the devastating nature of the disease, the drug is benefiting patients more than it is causing harm. Regulators approve it. Advertisement Months later, physicians prescribing the drug widely start to note a small number of patients are dying, despite the fact that no deaths were reported in a clinical trial of the drug. Similarly, the frequency of serious side effects rises dramatically, including some so severe that patients require hospitalization. The drug’s real-world safety profile appears worse than what was characterized in the small clinical trial. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [rare diseases](https://www.statnews.com/topic/rare-diseases/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") 2. Senior Writer, Biotech 1. [](https://x.com/adamfeuerstein "X") 2. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2024/03/Biotech-Scorecard-Logo-NoSTAT-640x290.png) ### STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-55908504-80x80.jpg) [Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths ](https://www.statnews.com/2026/08/11/stop-statins-age-75-lancet-study-suggests-safe-healthy-adults/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1260243913-80x80.jpeg) [MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them](https://www.statnews.com/2026/08/05/prostate-cancer-screening-biopsy-vs-mri-debate/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AP26223692576154-80x80.jpg) [The Lindsay Clancy case shows the limits of postpartum psychiatry](https://www.statnews.com/2026/08/12/lindsay-clancy-postpartum-psychosis-diagnosis-treatment-limits/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/STAT_AIBillingSystem_F1_3000-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care](https://www.statnews.com/2026/08/12/inside-commure-athelas-mad-dash-automate-health-care/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/Schett-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies](https://www.statnews.com/2026/08/12/boulevard-bio-georg-schett-antibody-therapies/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2025/08/VCFirms2025_LeftRailUnit-328x426.png) 2025 Edition: Ranking Biotech’s Top Venture Capital Firms ](https://reports.statnews.com/products/biotech-top-venture-capital-firms-2025) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2245399768-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [NIH plans to block international researchers on visas from accessing key funding avenue ](https://www.statnews.com/2026/08/07/nih-k99-pathways-independence-awards-scientists-on-visas-barred/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1666307366-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety](https://www.statnews.com/2026/08/05/china-clinical-trial-fatality-safety-questions-investigator-led-studies/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/C0508954-Tau_protein_clusters_TEM-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Study reveals new role for tau, a top target for Alzheimer’s drug development](https://www.statnews.com/2026/08/06/research-finds-how-tau-targets-cells-structure-alzheimers-drug-development/) 4. ![](https://www.statnews.com/wp-content/uploads/2023/04/AdobeStock_521699065_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment](https://www.statnews.com/2026/08/10/itm-radiopharma-fda-rejection/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2269935478-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed](https://www.statnews.com/2026/08/10/china-biotech-new-scrutiny-investigator-initiated-trials/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard August 6, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Biotech’s next big bet: A Tenax study of a heart failure treatment ](https://www.statnews.com/2026/08/06/tenax-study-heart-failure-preview/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard July 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Amylyx nears pivotal endocrine drug study readout ](https://www.statnews.com/2026/07/16/amylyx-bph-avexitide-biogen-diranersen-agios/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard July 9, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: 931 days. The drug approval scandal hiding in plain sight ](https://www.statnews.com/2026/07/09/northwest-biotherapeutics-brain-cancer-treatment/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard July 2, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Halfway into the year, biotech is booming ](https://www.statnews.com/2026/07/02/biotech-sector-booms-capricor-fda-meeting/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard June 18, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept ](https://www.statnews.com/2026/06/18/patrick-soon-shiong-pancreatic-cancer-abivax-concerns/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care ](https://www.statnews.com/2026/08/12/inside-commure-athelas-mad-dash-automate-health-care/) By [Casey Ross](https://www.statnews.com/staff/casey-ross/) and [Brittany Trang](https://www.statnews.com/staff/brittany-trang/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: The promise of radiopharmaceuticals smacks into safety concerns ](https://www.statnews.com/2026/08/10/radiopharmaceuticals-clinical-trials-progress-setbacks/) By [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety ](https://www.statnews.com/2026/08/05/china-clinical-trial-
## Related Clinical Research

- [California’s CalRx insulin rollout is slow to reach patients despite Newsom push](https://medichelpline.com/clinical-feed/stat-news-5-stat-newsom-promotes-affordable-insulin-but-california-s-generic-label-is-off.md)
- [Sionna’s SION-719 showed no benefit vs. Trikafta in Phase 2 add-on trial](https://medichelpline.com/clinical-feed/stat-news-0-stat-sionna-s-experimental-cystic-fibrosis-pill-falls-flat-in-mid-stage-trial.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)
- [Which Exercises Best Target Blood Pressure, Blood Sugar, and Cholesterol in Metabolic Syndrome?](https://medichelpline.com/clinical-feed/medical-news-today-0-how-do-different-exercises-target-blood-pressure-blood-sugar-and-cholesterol.md)
- [Planetary Health Diet Linked to Lower Cardiovascular Risk in Postmenopausal Women](https://medichelpline.com/clinical-feed/medical-news-today-0-plant-based-planetary-health-diet-could-help-protect-heart-health.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.